Catalyst Pharmaceuticals (NASDAQ: CPRX)
Catalyst Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Catalyst Pharmaceuticals Company Info
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
News & Analysis
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
These two healthcare stocks may be deeply undervalued.
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024
With multiple drugs on the market and revenue ramping up, the sky's the limit.
3 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies are still in the early innings of their growth potential.
2 Robinhood Stocks With Market-Beating Potential
These diamonds in the rough won't stay down.
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
When evaluating investments, it helps to keep quarterly performance in context.
2 Top Growth Stocks That Can Withstand an Economic Downturn
These two drugmakers should march higher in 2023 and beyond.
1 Growth Stock to Buy Before the Next Bull Market
The stock is on a roll, and the company just made a major new purchase.
2 Growth Stocks to Invest $1,000 in Right Now
Both of these biopharmas have major catalysts that are in play or drawing near.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.